Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Four-year follow-up from a Phase II study of obinutuzumab, ibrutinib, and venetoclax in CLL

Kerry Rogers • 3 Jun 2022
ASCO 2022
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Obinutuzumab Venetoclax

Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses four-year folllow-up results of a Phase II study of obinutuzumab, ibrutinib, and venetoclax in patients with chronic lymphocytic leukemia (CLL). At extended follow-up, remissions remain durable after fixed duration obinutuzumab, ibrutinib, and venetoclax. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Kerry Rogers

2:20
The effect of ibrutinib dose-reduction on outcomes of patients with CLL/SLL: real-world evidence
Kerry Rogers • 8 Dec 2023
4:07
The long-term impact of early lenalidomide treatment on infections and secondary neoplasms in CLL
Kerry Rogers • 8 Dec 2023
5:34
Venetoclax added to ibrutinib in patients with CLL with molecular resistance to BTKi treatment
Kerry Rogers • 8 Dec 2023
1:18
Comorbidity and geriatric assessment tools in routine practice for CLL patients
Kerry Rogers • 7 Oct 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals